Tocira (tocilizumab biosimilar) / Hetero - LARVOL DELTA

Real-world Effectiveness of Interleukin-6 Receptor Inhibitors in Patients with Steroid Refractory Polymyalgia Rheumatica (CCR 2023) - "In the real-world, IL-6Ri was a more effective steroid sparing agent than cIM in steroid refractory PMR."

Hetero’s Biosimilar version of Tocilizumab receives EUA from DCGI for treatment of Covid-19 (The Hindu Business Line) - "Hetero announced on Monday that the Drug Controller General of India (DCGI) has issued Emergency Use Authorisation (EUA) for the generic version of Tocilizumab in India for restricted use...This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab....Hetero’s Tocira (Tocilizumab) will be marketed by its associate company Hetero Healthcare in India with the support of its strong distribution network across the country....Hetero’s Tocilizumab 400 mg/20 ml is the biosimilar version of Roche’s Actemra/RoActemra, and will be available from September-end."

Launch non-US • Non-US regulatory • Infectious Disease • Novel Coronavirus Disease